Treatment with the dual SRC/ABL-inhibitor dasatinib partly restored the drug sensitivity in the resistant cell line, but had no effect on parental cell line, suggesting that up-regulation of SRC and SRC-related pathways, and of downstream survival pathways, could be strictly associated with the resistance to Chk1 inhibitors in MCL. The gene discussed is SRC; the disease is mantle cell lymphoma.